FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:ESR1-MTHFD1L

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: ESR1-MTHFD1L
FusionPDB ID: 27544
FusionGDB2.0 ID: 27544
HgeneTgene
Gene symbol

ESR1

MTHFD1L

Gene ID

2099

25902

Gene nameestrogen receptor 1methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1 like
SynonymsER|ESR|ESRA|ESTRR|Era|NR3A1FTHFSDC1|MTC1THFS|dJ292B18.2
Cytomap

6q25.1-q25.2

6q25.1

Type of geneprotein-codingprotein-coding
Descriptionestrogen receptorE2 receptor alphaER-alphaestradiol receptorestrogen nuclear receptor alphaestrogen receptor alpha E1-E2-1-2estrogen receptor alpha E1-N2-E2-1-2nuclear receptor subfamily 3 group A member 1oestrogen receptor alphamonofunctional C1-tetrahydrofolate synthase, mitochondrial10-formyl-THF synthetaseformyltetrahydrofolate synthetase domain containing 1
Modification date2020032920200313
UniProtAcc

P03372

Main function of 5'-partner protein: FUNCTION: Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full-length receptor. Essential for MTA1-mediated transcriptional regulation of BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit isoform 1. {ECO:0000269|PubMed:10681512, ECO:0000269|PubMed:10816575, ECO:0000269|PubMed:11477071, ECO:0000269|PubMed:11682626, ECO:0000269|PubMed:14764652, ECO:0000269|PubMed:15078875, ECO:0000269|PubMed:15891768, ECO:0000269|PubMed:16043358, ECO:0000269|PubMed:16617102, ECO:0000269|PubMed:16684779, ECO:0000269|PubMed:17922032, ECO:0000269|PubMed:17932106, ECO:0000269|PubMed:18247370, ECO:0000269|PubMed:19350539, ECO:0000269|PubMed:20074560, ECO:0000269|PubMed:20705611, ECO:0000269|PubMed:21330404, ECO:0000269|PubMed:22083956, ECO:0000269|PubMed:7651415, ECO:0000269|PubMed:9328340}.

Q6UB35

Main function of 5'-partner protein: FUNCTION: May provide the missing metabolic reaction required to link the mitochondria and the cytoplasm in the mammalian model of one-carbon folate metabolism in embryonic an transformed cells complementing thus the enzymatic activities of MTHFD2. {ECO:0000250, ECO:0000269|PubMed:16171773}.
Ensembl transtripts involved in fusion geneENST idsENST00000482101, ENST00000206249, 
ENST00000338799, ENST00000406599, 
ENST00000427531, ENST00000440973, 
ENST00000443427, ENST00000456483, 
ENST00000367321, ENST00000478643, 
ENST00000367307, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score21 X 18 X 8=302414 X 17 X 13=3094
# samples 3527
** MAII scorelog2(35/3024*10)=-3.11103131238874
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(27/3094*10)=-3.51844188439821
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: ESR1 [Title/Abstract] AND MTHFD1L [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: ESR1 [Title/Abstract] AND MTHFD1L [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)ESR1(152129499)-MTHFD1L(151330954), # samples:2
ESR1(152265643)-MTHFD1L(151330955), # samples:2
Anticipated loss of major functional domain due to fusion event.ESR1-MTHFD1L seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ESR1-MTHFD1L seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ESR1-MTHFD1L seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ESR1-MTHFD1L seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ESR1-MTHFD1L seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF.
ESR1-MTHFD1L seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
ESR1-MTHFD1L seems lost the major protein functional domain in Hgene partner, which is a transcription factor due to the frame-shifted ORF.
ESR1-MTHFD1L seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF.
ESR1-MTHFD1L seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
ESR1-MTHFD1L seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneESR1

GO:0006366

transcription by RNA polymerase II

15831516

HgeneESR1

GO:0010629

negative regulation of gene expression

21695196

HgeneESR1

GO:0030520

intracellular estrogen receptor signaling pathway

9841876

HgeneESR1

GO:0032355

response to estradiol

15304487

HgeneESR1

GO:0043124

negative regulation of I-kappaB kinase/NF-kappaB signaling

7651415|16043358

HgeneESR1

GO:0043433

negative regulation of DNA-binding transcription factor activity

10816575

HgeneESR1

GO:0043627

response to estrogen

11581164

HgeneESR1

GO:0045893

positive regulation of transcription, DNA-templated

9841876|20074560

HgeneESR1

GO:0045899

positive regulation of RNA polymerase II transcriptional preinitiation complex assembly

9841876

HgeneESR1

GO:0045944

positive regulation of transcription by RNA polymerase II

11544182|12047722|15345745|15831516|18563714

HgeneESR1

GO:0051091

positive regulation of DNA-binding transcription factor activity

9328340|10681512

HgeneESR1

GO:0071392

cellular response to estradiol stimulus

15831516

TgeneMTHFD1L

GO:0006760

folic acid-containing compound metabolic process

12937168

TgeneMTHFD1L

GO:0009257

10-formyltetrahydrofolate biosynthetic process

12937168

TgeneMTHFD1L

GO:0015942

formate metabolic process

16171773



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr6:152129499/chr6:151330954)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across ESR1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across MTHFD1L (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000440973ESR1chr6152382259+ENST00000367321MTHFD1Lchr6151330954+294417393702550726
ENST00000338799ESR1chr6152382259+ENST00000367321MTHFD1Lchr6151330954+4034282914603640726
ENST00000456483ESR1chr6152382259+ENST00000367321MTHFD1Lchr6151330954+245612512182062614
ENST00000443427ESR1chr6152382259+ENST00000367321MTHFD1Lchr6151330954+283516302612441726
ENST00000206249ESR1chr6152382259+ENST00000367321MTHFD1Lchr6151330954+293617313622542726
ENST00000406599ESR1chr6152382259+ENST00000367321MTHFD1Lchr6151330954+20258202341631465
ENST00000427531ESR1chr6152382259+ENST00000367321MTHFD1Lchr6151330954+228710822051893562
ENST00000440973ESR1chr6152265643+ENST00000367321MTHFD1Lchr6151330955+267114663702277635
ENST00000338799ESR1chr6152265643+ENST00000367321MTHFD1Lchr6151330955+3761255614603367635
ENST00000443427ESR1chr6152265643+ENST00000367321MTHFD1Lchr6151330955+256213572612168635
ENST00000206249ESR1chr6152265643+ENST00000367321MTHFD1Lchr6151330955+266314583622269635
ENST00000427531ESR1chr6152265643+ENST00000367321MTHFD1Lchr6151330955+20148092051620471

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000440973ENST00000367321ESR1chr6152382259+MTHFD1Lchr6151330954+0.0025102860.9974897
ENST00000338799ENST00000367321ESR1chr6152382259+MTHFD1Lchr6151330954+0.0013212120.99867874
ENST00000456483ENST00000367321ESR1chr6152382259+MTHFD1Lchr6151330954+0.0026261130.99737394
ENST00000443427ENST00000367321ESR1chr6152382259+MTHFD1Lchr6151330954+0.0023272630.99767274
ENST00000206249ENST00000367321ESR1chr6152382259+MTHFD1Lchr6151330954+0.0020635690.9979365
ENST00000406599ENST00000367321ESR1chr6152382259+MTHFD1Lchr6151330954+0.0031695520.9968304
ENST00000427531ENST00000367321ESR1chr6152382259+MTHFD1Lchr6151330954+0.0017158330.99828416
ENST00000440973ENST00000367321ESR1chr6152265643+MTHFD1Lchr6151330955+0.0036151390.99638486
ENST00000338799ENST00000367321ESR1chr6152265643+MTHFD1Lchr6151330955+0.001826680.99817336
ENST00000443427ENST00000367321ESR1chr6152265643+MTHFD1Lchr6151330955+0.0035336940.9964663
ENST00000206249ENST00000367321ESR1chr6152265643+MTHFD1Lchr6151330955+0.0031022310.9968978
ENST00000427531ENST00000367321ESR1chr6152265643+MTHFD1Lchr6151330955+0.0024127790.9975872

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ESR1-MTHFD1L

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
ESR1chr6152265643MTHFD1Lchr61513309551357365ELVHMINWAKRVPVTEAGFGADIGME
ESR1chr6152265643MTHFD1Lchr61513309551458365ELVHMINWAKRVPVTEAGFGADIGME
ESR1chr6152265643MTHFD1Lchr61513309551466365ELVHMINWAKRVPVTEAGFGADIGME
ESR1chr6152265643MTHFD1Lchr61513309552556365ELVHMINWAKRVPVTEAGFGADIGME
ESR1chr6152265643MTHFD1Lchr6151330955809201ELVHMINWAKRVPVTEAGFGADIGME
ESR1chr6152382259MTHFD1Lchr61513309541082292EFVCLKSIILLNSVTEAGFGADIGME
ESR1chr6152382259MTHFD1Lchr61513309541251344EFVCLKSIILLNSVTEAGFGADIGME
ESR1chr6152382259MTHFD1Lchr61513309541630456EFVCLKSIILLNSVTEAGFGADIGME
ESR1chr6152382259MTHFD1Lchr61513309541731456EFVCLKSIILLNSVTEAGFGADIGME
ESR1chr6152382259MTHFD1Lchr61513309541739456EFVCLKSIILLNSVTEAGFGADIGME
ESR1chr6152382259MTHFD1Lchr61513309542829456EFVCLKSIILLNSVTEAGFGADIGME
ESR1chr6152382259MTHFD1Lchr6151330954820195EFVCLKSIILLNSVTEAGFGADIGME

Top

Potential FusionNeoAntigen Information of ESR1-MTHFD1L in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ESR1-MTHFD1L_152265643_151330955.msa
ESR1-MTHFD1L_152382259_151330954.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ESR1-MTHFD1Lchr6152265643chr61513309551458HLA-B27:04KRVPVTEAGF0.99990.6543919
ESR1-MTHFD1Lchr6152265643chr61513309551458HLA-B56:01VPVTEAGFGA0.9090.74851121
ESR1-MTHFD1Lchr6152265643chr61513309551458HLA-C01:17RVPVTEAGF0.08330.95231019
ESR1-MTHFD1Lchr6152265643chr61513309551458HLA-C07:95KRVPVTEAGF0.99750.5864919
ESR1-MTHFD1Lchr6152265643chr61513309551458HLA-C07:19KRVPVTEAGF0.99690.7593919
ESR1-MTHFD1Lchr6152265643chr61513309551458HLA-C07:46KRVPVTEAGF0.98910.8828919
ESR1-MTHFD1Lchr6152265643chr61513309551458HLA-B54:01VPVTEAGFGA0.9810.87041121
ESR1-MTHFD1Lchr6152265643chr61513309551458HLA-C01:02RVPVTEAGF0.01250.94641019
ESR1-MTHFD1Lchr6152265643chr61513309551458HLA-B27:10KRVPVTEAGF0.99990.6639919
ESR1-MTHFD1Lchr6152265643chr61513309551458HLA-B27:06KRVPVTEAGF0.99970.6759919
ESR1-MTHFD1Lchr6152265643chr61513309551458HLA-C07:01KRVPVTEAGF0.99850.5784919
ESR1-MTHFD1Lchr6152265643chr61513309551458HLA-C07:22KRVPVTEAGF0.99310.6831919
ESR1-MTHFD1Lchr6152265643chr61513309551458HLA-B15:68KRVPVTEAGF0.91460.6775919
ESR1-MTHFD1Lchr6152265643chr61513309551458HLA-B55:02VPVTEAGFGA0.8880.77251121
ESR1-MTHFD1Lchr6152382259chr61513309541731HLA-A02:22ILLNSVTEA0.9960.5626817
ESR1-MTHFD1Lchr6152382259chr61513309541731HLA-A02:11ILLNSVTEA0.99390.5286817
ESR1-MTHFD1Lchr6152382259chr61513309541731HLA-A02:27ILLNSVTEA0.99280.581817
ESR1-MTHFD1Lchr6152382259chr61513309541731HLA-A02:13ILLNSVTEA0.99260.6256817
ESR1-MTHFD1Lchr6152382259chr61513309541731HLA-A02:21ILLNSVTEA0.99210.6178817
ESR1-MTHFD1Lchr6152382259chr61513309541731HLA-A30:08KSIILLNSV0.98830.702514
ESR1-MTHFD1Lchr6152382259chr61513309541731HLA-A02:38ILLNSVTEA0.98190.5785817
ESR1-MTHFD1Lchr6152382259chr61513309541731HLA-A02:04ILLNSVTEA0.97520.601817
ESR1-MTHFD1Lchr6152382259chr61513309541731HLA-A02:35ILLNSVTEA0.92390.5048817
ESR1-MTHFD1Lchr6152382259chr61513309541731HLA-C15:02KSIILLNSV0.99950.8297514
ESR1-MTHFD1Lchr6152382259chr61513309541731HLA-A02:03ILLNSVTEA0.99620.6078817
ESR1-MTHFD1Lchr6152382259chr61513309541731HLA-A02:06ILLNSVTEA0.99210.6178817
ESR1-MTHFD1Lchr6152382259chr61513309541731HLA-A02:14ILLNSVTEA0.99160.5485817

Top

Potential FusionNeoAntigen Information of ESR1-MTHFD1L in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ESR1-MTHFD1L_152265643_151330955.msa
ESR1-MTHFD1L_152382259_151330954.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1113VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1113LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1117VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1117LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1117ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1117HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1141VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1148VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1152VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1152LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1152ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1152HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1189VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1189LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1189HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1189ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1192VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1308VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1319VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1331VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1331LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1332VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1343VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1343LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1348VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1353VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1354VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1354LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1370VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1372VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1376VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1376LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1377VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1377LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1384VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1401VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1401LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1401ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1401HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1404VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1404LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1404ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1405VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1405LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1405ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1405HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1406VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1407VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1407LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1408VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1408LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1408ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1408HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1411VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1411LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1412VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1414VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1414LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1416VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1416LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1418VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1418LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1418HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1418ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1420VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1423VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1423LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1423ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1423HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1426VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1426LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1426ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1426HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1428VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1428LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1428ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1428HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1429VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1431VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1431LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1432VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1432LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1432ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1433VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1433LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1434VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1434LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1435VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1435LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1435ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1435HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1436VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1436LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1437VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1438VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1438LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1438ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1438HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1439VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1439LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1442VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1442LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1443VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1443LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1443HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1443ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1444VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1444LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1445VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1445LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1445ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1445HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1450VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1450LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1450ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1454VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1454LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1454ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1454HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1455VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1455LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1455ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1455HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1456VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1456LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1456ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1456HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1458VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1458LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1458ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1458HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1459VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1459LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1459ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1459HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1460VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1460LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1460ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1460HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1461VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1461LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1461ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1462VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1462LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1462ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1462HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1464VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1464LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1464ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1464HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1465VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1465LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1468VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1468LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1470VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1470LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1470ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1470HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1471VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1471LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1471ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1472VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1472LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1472ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1472HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1473VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1473LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1474VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1475VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1475LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1475ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1475HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1481VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1481LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1482VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1482LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1482ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1482HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1483VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1486VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1486LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1486ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1486HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1487VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1487LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1487ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1487HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1488VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1488LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1488ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1488HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1490VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1490LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1490ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1490HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1491VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1491LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1491ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1491HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1493VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1495VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1495LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1495ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1495HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1496VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1496LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1496ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1496HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1497VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1497LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1497ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1497HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1499VHMINWAKRVPVTEA217
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1499LVHMINWAKRVPVTE116
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1499ELVHMINWAKRVPVT015
ESR1-MTHFD1Lchr6152265643chr61513309551458DRB1-1499HMINWAKRVPVTEAG318
ESR1-MTHFD1Lchr6152382259chr61513309541731DRB3-0201KSIILLNSVTEAGFG520
ESR1-MTHFD1Lchr6152382259chr61513309541731DRB3-0201LKSIILLNSVTEAGF419
ESR1-MTHFD1Lchr6152382259chr61513309541731DRB3-0205KSIILLNSVTEAGFG520
ESR1-MTHFD1Lchr6152382259chr61513309541731DRB3-0211KSIILLNSVTEAGFG520
ESR1-MTHFD1Lchr6152382259chr61513309541731DRB3-0214KSIILLNSVTEAGFG520
ESR1-MTHFD1Lchr6152382259chr61513309541731DRB3-0224KSIILLNSVTEAGFG520
ESR1-MTHFD1Lchr6152382259chr61513309541731DRB3-0224LKSIILLNSVTEAGF419

Top

Fusion breakpoint peptide structures of ESR1-MTHFD1L

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
6453NWAKRVPVTEAGFGESR1MTHFD1Lchr6152265643chr61513309551458
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
8645SIILLNSVTEAGFGESR1MTHFD1Lchr6152382259chr61513309541731

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ESR1-MTHFD1L

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B53:011A1O6453NWAKRVPVTEAGFG-1.20162-2.23692
HLA-B51:011E286453NWAKRVPVTEAGFG-4.67742-5.71272
HLA-B57:032BVO6453NWAKRVPVTEAGFG-3.57384-3.68724
HLA-A03:012XPG6453NWAKRVPVTEAGFG-2.81241-3.84771
HLA-A03:012XPG6453NWAKRVPVTEAGFG-2.75108-2.86448
HLA-B14:023BVN6453NWAKRVPVTEAGFG-6.6298-6.7432
HLA-B14:023BVN6453NWAKRVPVTEAGFG-5.03588-6.07118
HLA-B27:093CZF6453NWAKRVPVTEAGFG-2.72034-3.75564
HLA-B44:033DX76453NWAKRVPVTEAGFG-0.953592-1.98889
HLA-B52:013W396453NWAKRVPVTEAGFG-5.17052-5.28392
HLA-B52:013W396453NWAKRVPVTEAGFG-2.67174-3.70704
HLA-B18:014JQV6453NWAKRVPVTEAGFG-3.88279-3.99619
HLA-B18:014JQV6453NWAKRVPVTEAGFG-2.06796-3.10326
HLA-A11:014UQ26453NWAKRVPVTEAGFG-8.93359-9.04699
HLA-A11:014UQ26453NWAKRVPVTEAGFG-8.08854-9.12384
HLA-A24:025HGA6453NWAKRVPVTEAGFG-6.7667-6.8801
HLA-A24:025HGA6453NWAKRVPVTEAGFG-4.92764-5.96294
HLA-B57:015VUD6453NWAKRVPVTEAGFG-2.30317-3.33847
HLA-B27:056PYJ6453NWAKRVPVTEAGFG-4.30074-4.41414
HLA-B27:056PYJ6453NWAKRVPVTEAGFG-2.70769-3.74299
HLA-B27:036PZ56453NWAKRVPVTEAGFG-3.25646-4.29176
HLA-B27:036PZ56453NWAKRVPVTEAGFG-1.00133-1.11473
HLA-B44:053DX86453NWAKRVPVTEAGFG-5.00036-5.11376
HLA-B44:053DX86453NWAKRVPVTEAGFG-4.13613-5.17143
HLA-B07:025EO06453NWAKRVPVTEAGFG-1.03752-2.07282
HLA-A02:016TDR6453NWAKRVPVTEAGFG-5.74233-6.77763
HLA-B14:023BVN8645SIILLNSVTEAGFG-7.15543-7.26883
HLA-B14:023BVN8645SIILLNSVTEAGFG-4.77435-5.80965
HLA-B52:013W398645SIILLNSVTEAGFG-6.80875-6.92215
HLA-B52:013W398645SIILLNSVTEAGFG-4.20386-5.23916
HLA-A11:014UQ28645SIILLNSVTEAGFG-7.5194-8.5547
HLA-A11:014UQ28645SIILLNSVTEAGFG-6.9601-7.0735
HLA-A24:025HGA8645SIILLNSVTEAGFG-7.52403-7.63743
HLA-A24:025HGA8645SIILLNSVTEAGFG-5.82433-6.85963
HLA-B27:056PYJ8645SIILLNSVTEAGFG-3.28285-4.31815
HLA-B44:053DX88645SIILLNSVTEAGFG-5.91172-6.94702
HLA-B44:053DX88645SIILLNSVTEAGFG-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of ESR1-MTHFD1L

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
ESR1-MTHFD1Lchr6152265643chr61513309551019RVPVTEAGFGGGTGCCAGTGACCGAAGCTGGCTTTG
ESR1-MTHFD1Lchr6152265643chr61513309551121VPVTEAGFGATGCCAGTGACCGAAGCTGGCTTTGGTGCTG
ESR1-MTHFD1Lchr6152265643chr6151330955919KRVPVTEAGFAGAGGGTGCCAGTGACCGAAGCTGGCTTTG
ESR1-MTHFD1Lchr6152382259chr6151330954514KSIILLNSVAATCTATTATTTTGCTTAATTCTGTGA
ESR1-MTHFD1Lchr6152382259chr6151330954817ILLNSVTEATTTTGCTTAATTCTGTGACCGAAGCTG

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
ESR1-MTHFD1Lchr6152265643chr6151330955015ELVHMINWAKRVPVTAGCTGGTTCACATGATCAACTGGGCGAAGAGGGTGCCAGTGACCG
ESR1-MTHFD1Lchr6152265643chr6151330955116LVHMINWAKRVPVTETGGTTCACATGATCAACTGGGCGAAGAGGGTGCCAGTGACCGAAG
ESR1-MTHFD1Lchr6152265643chr6151330955217VHMINWAKRVPVTEATTCACATGATCAACTGGGCGAAGAGGGTGCCAGTGACCGAAGCTG
ESR1-MTHFD1Lchr6152265643chr6151330955318HMINWAKRVPVTEAGACATGATCAACTGGGCGAAGAGGGTGCCAGTGACCGAAGCTGGCT
ESR1-MTHFD1Lchr6152382259chr6151330954419LKSIILLNSVTEAGFTCAAATCTATTATTTTGCTTAATTCTGTGACCGAAGCTGGCTTTG
ESR1-MTHFD1Lchr6152382259chr6151330954520KSIILLNSVTEAGFGAATCTATTATTTTGCTTAATTCTGTGACCGAAGCTGGCTTTGGTG

Top

Information of the samples that have these potential fusion neoantigens of ESR1-MTHFD1L

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
BRCAESR1-MTHFD1Lchr6152265643ENST00000206249chr6151330955ENST00000367321TCGA-BH-A5J0-01A
OVESR1-MTHFD1Lchr6152382259ENST00000206249chr6151330954ENST00000367321TCGA-04-1517

Top

Potential target of CAR-T therapy development for ESR1-MTHFD1L

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to ESR1-MTHFD1L

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to ESR1-MTHFD1L

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource